CN111542335A - 炎症性肠病的治疗药 - Google Patents

炎症性肠病的治疗药 Download PDF

Info

Publication number
CN111542335A
CN111542335A CN201880084992.7A CN201880084992A CN111542335A CN 111542335 A CN111542335 A CN 111542335A CN 201880084992 A CN201880084992 A CN 201880084992A CN 111542335 A CN111542335 A CN 111542335A
Authority
CN
China
Prior art keywords
inflammatory bowel
bowel disease
peptide
amino acid
dss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880084992.7A
Other languages
English (en)
Chinese (zh)
Inventor
玉井克人
新保敬史
山崎尊彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stremium GmbH
University of Osaka NUC
Original Assignee
Stremium GmbH
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stremium GmbH, Osaka University NUC filed Critical Stremium GmbH
Publication of CN111542335A publication Critical patent/CN111542335A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201880084992.7A 2017-12-01 2018-11-30 炎症性肠病的治疗药 Pending CN111542335A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593310P 2017-12-01 2017-12-01
US62/593,310 2017-12-01
JP2018-020686 2018-02-08
JP2018020686 2018-02-08
PCT/JP2018/044122 WO2019107530A1 (ja) 2017-12-01 2018-11-30 炎症性腸疾患の治療薬

Publications (1)

Publication Number Publication Date
CN111542335A true CN111542335A (zh) 2020-08-14

Family

ID=66664517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880084992.7A Pending CN111542335A (zh) 2017-12-01 2018-11-30 炎症性肠病的治疗药

Country Status (5)

Country Link
US (1) US11298403B2 (https=)
EP (1) EP3718561A4 (https=)
JP (2) JPWO2019107530A1 (https=)
CN (1) CN111542335A (https=)
WO (1) WO2019107530A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023138644A1 (zh) * 2022-01-21 2023-07-27 四川好医生攀西药业有限责任公司 多肽化合物及其治疗肠炎的用途
CN116693612A (zh) * 2023-06-28 2023-09-05 禾美生物科技(浙江)有限公司 一种环肽及其用途
CN117224655A (zh) * 2023-09-14 2023-12-15 大连医科大学 蝎毒耐热合成肽(svhrsp)在制备治疗肠道炎症的药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
WO2020071520A1 (ja) * 2018-10-05 2020-04-09 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
CA3117107A1 (en) * 2018-10-25 2020-04-30 Osaka University Therapeutic agent for cartilage disorder
IL296982B2 (en) * 2020-04-03 2026-04-01 Stemrim Inc Peptide with mesenchymal stem cell migration activity
EP4147711A4 (en) * 2020-04-20 2024-04-24 Shionogi & Co., Ltd FORMULATION WITH A HMGB1 PARTIAL PEPTIDE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046345A2 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
US20080038309A1 (en) * 2004-09-03 2008-02-14 Creabilis Therapeutics S.P.A. Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human Box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
CN107188948A (zh) * 2011-04-26 2017-09-22 吉诺米克斯股份有限公司 用于诱导组织再生的肽及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238680B2 (https=) 1972-12-27 1977-09-30
US4732155A (en) 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US5133755A (en) 1986-01-28 1992-07-28 Thm Biomedical, Inc. Method and apparatus for diodegradable, osteogenic, bone graft substitute device
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3018313B2 (ja) 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20050101564A1 (en) 1996-04-02 2005-05-12 Pilarski Linda M. Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
ATE440602T1 (de) 1999-07-28 2009-09-15 Univ Leland Stanford Junior Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
JP2003517858A (ja) 1999-11-05 2003-06-03 ジェリジーン メディカル コーポレーション 老齢関連の軟組織の欠陥の増強と修復
EP1114862A3 (de) 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
JP3421741B2 (ja) 2000-05-18 2003-06-30 筑波大学長 人工骨髄、血球細胞の増殖方法
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
DE10121254A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
EP1390058A2 (en) 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN100447154C (zh) 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CA2467557A1 (en) 2001-11-19 2003-05-30 Kyowa Hakko Kogyo Co., Ltd. Agent which mobilizes multipotential stem cells from tissues to peripheral blood
KR100930139B1 (ko) 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
FR2833609B1 (fr) 2001-12-19 2004-12-03 Natural Implant Dispositif de prelevement cellulaire ou tissulaire en phase active et utilisations
AU2003228099A1 (en) 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
US7553488B2 (en) 2002-07-05 2009-06-30 UNIVERSITé LAVAL Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions
WO2004042033A2 (en) 2002-11-01 2004-05-21 The Board Of Trustees Of The Leland Stanford Junior University Circulating stem cells and uses related thereto
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
WO2004061456A2 (de) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
EP1608397B1 (en) 2003-03-28 2008-10-15 Universite Laval S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
CN1193092C (zh) 2003-03-28 2005-03-16 浙江大学 骨髓间充质干细胞分离和体外扩增培养方法
US20090069227A9 (en) 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
AU2004242091C1 (en) 2003-05-07 2009-12-24 La Jolla Institute For Molecular Medicine Administration of hyaluronic acid to enhance the function of transplanted stem cells
US20050014255A1 (en) 2003-05-29 2005-01-20 Board Of Regents, The University Of Texas System Stem cells for clinical and commercial uses
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
JP2008507505A (ja) 2004-07-20 2008-03-13 プロヴィンシア・イタリアーナ・デッラ・コングレガチォーネ・フィリ・デッリマコラータ・コンセチォーネ−イスティトゥト・デルモパティコ・デッリマコラータ−アイ・アール・シー・シー・エス 創傷治癒のためのｈｍｇｂ１の使用
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ITRM20050032A1 (it) 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
JP5103626B2 (ja) 2005-01-27 2012-12-19 財団法人ヒューマンサイエンス振興財団 間葉系幹細胞を含む細胞シート
ES2345837T3 (es) 2005-03-23 2010-10-04 Biosafe S.A. Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa.
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20100280493A1 (en) 2005-06-23 2010-11-04 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
WO2007015546A1 (ja) 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
US20090155853A1 (en) 2005-11-18 2009-06-18 Gary Nabel Non-viral gene delivery complex
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
CA2640087A1 (en) 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP4982739B2 (ja) 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
ES2629086T3 (es) 2006-10-30 2017-08-07 Genomix Co., Ltd. Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
CA2629652A1 (en) 2007-04-24 2008-10-24 Yaojiong Wu Compositions for preventing or treating skin defects and methods of use thereof
US8114668B2 (en) 2007-05-14 2012-02-14 Cardiac Pacemakers, Inc. Composition for cold storage of stem cells
US8673580B2 (en) 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5814549B2 (ja) 2008-04-30 2015-11-17 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
ES2609006T3 (es) 2009-10-16 2017-04-18 Rutgers, The State University Of New Jersey Procedimeinto de tratamiento de lesión crónica de tejido nervioso usando una estrategia de terapia celular
CA2773356A1 (en) 2009-10-20 2011-04-28 Maine Medical Center Compositions and methods for treating inflammation and fibrosis
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
EP2529235B1 (en) 2010-01-29 2019-03-06 Metanomics GmbH Means and methods for diagnosing heart failure in a subject
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
CN102443064A (zh) 2011-11-03 2012-05-09 刘誉 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用
ES2661500T3 (es) 2012-07-26 2018-04-02 Ospedale San Raffaele S.R.L. Variantes de HMGB1 y sus usos
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
ES2660420T3 (es) 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
GB2514424A (en) 2013-05-25 2014-11-26 Univ Dublin Therapies for Cardiomyopathy
GB201508337D0 (en) 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US20200038486A1 (en) 2017-04-07 2020-02-06 StemRIM Inc. Therapeutic medicine for fibrous disease
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
WO2020071520A1 (ja) 2018-10-05 2020-04-09 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046345A2 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
US20080038309A1 (en) * 2004-09-03 2008-02-14 Creabilis Therapeutics S.P.A. Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human Box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
CN107188948A (zh) * 2011-04-26 2017-09-22 吉诺米克斯股份有限公司 用于诱导组织再生的肽及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHENG, X等: "Adeno - associated virus - mediated colonic secretory expression of HMGB1 A box attenuates experimental colitis in mice", 《J GENE MED》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023138644A1 (zh) * 2022-01-21 2023-07-27 四川好医生攀西药业有限责任公司 多肽化合物及其治疗肠炎的用途
CN116693612A (zh) * 2023-06-28 2023-09-05 禾美生物科技(浙江)有限公司 一种环肽及其用途
CN116693612B (zh) * 2023-06-28 2025-02-18 禾美生物科技(浙江)有限公司 一种环肽及其用途
CN117224655A (zh) * 2023-09-14 2023-12-15 大连医科大学 蝎毒耐热合成肽(svhrsp)在制备治疗肠道炎症的药物中的应用
CN117224655B (zh) * 2023-09-14 2024-05-14 大连医科大学 蝎毒耐热合成肽(svhrsp)在制备治疗肠道炎症的药物中的应用

Also Published As

Publication number Publication date
WO2019107530A1 (ja) 2019-06-06
JP2023134616A (ja) 2023-09-27
US11298403B2 (en) 2022-04-12
EP3718561A1 (en) 2020-10-07
US20200384074A1 (en) 2020-12-10
JPWO2019107530A1 (ja) 2020-11-26
JP7590724B2 (ja) 2024-11-27
EP3718561A4 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
JP7590724B2 (ja) 炎症性腸疾患の治療薬
JP6552117B2 (ja) 敗血症の予防治療剤
JP7386455B2 (ja) 乾癬の治療薬
JP2022095884A (ja) 単離ミトコンドリアを含む関節リウマチの予防または治療のための医薬組成物
CN110621331A (zh) 纤维化疾病的治疗药物
TW201904607A (zh) 用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
JP6498210B2 (ja) 炎症関連疾患の治療と予防のためのｐ６２／ｓｑｓｔｍ１に関する方法と組成物
JP6166858B2 (ja) 細胞内損傷の治療のための組成物および方法
KR20180056628A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
CN110494154A (zh) 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂
CN102389413A (zh) 用于治疗糖尿病的组合物及其应用
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
CN107847565A (zh) 用于肌肉减少症治疗的包括胰高血糖素样肽‑1 受体激动剂的药物组合物
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
TWI828155B (zh) 吡咯并嘧啶類化合物的用途
BRPI0923832B1 (pt) Uso de um peptídeo tipo apl para o tratamento de doenças inflamatórias intestinais e diabetes tipo 1.
CN112567037B (zh) 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途
US11400137B2 (en) Rectal insulin for treatment of inflammatory bowel diseases
CN104853778A (zh) 用于肌萎缩性侧索硬化的治疗剂
CN118001373B (zh) 一种治疗骨关节炎的药物
WO2018159787A1 (ja) 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
JP4914344B2 (ja) 虚血／再灌流障害治療用のアドレノメデュリン及びアドレノメデュリン結合タンパク質
US20250235506A1 (en) Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use
KR20210082478A (ko) 연골 질환의 치료약
JP2024020797A (ja) 筋萎縮の治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination